A recent study from the Dutch Pancreatic Cancer Group showed that PDAC surveillance in germline carriers of CDKN2A/p16 pathogenic variant resulted in early detection with resectable disease and better overall compared survival compared with cases diagnosed outside of a surveillance program [26]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.